Led · Equity · Feb 2026

Exact Imaging is a Toronto-based medical device company focused on high-resolution micro-ultrasound technology for urologic imaging. Its flagship product, the ExactVu™ prostate biopsy platform, is built on a portfolio of more than 100 patents and is designed to improve prostate cancer detection accuracy. The company has achieved notable clinical validation, including publication of its OPTIMUM study in JAMA showing non-inferiority to MRI-fusion biopsy in biopsy-naïve men; the results were highlighted in the “Game Changer” session at the European Association of Urology Congress. Commercially, Exact Imaging has established over 300 customer installations worldwide and expanded its distribution network across North America, Europe, Asia, and Latin America. Recent initiatives include launching a dedicated North American salesforce and signing additional international distributors. The newly raised capital will accelerate global sales efforts and further drive market adoption of the ExactVu™ system.

Led · Series A · Sep 2024

Segmed provides real-world medical imaging data to life-sciences, health care and technology firms via a proprietary platform that acquires, de-identifies, standardizes, and delivers imaging studies. The company supports biopharmaceutical R&D, AI/ML development and real-world imaging data (RWiD) use cases. Segmed partners with health-care locations and imaging clinics across five continents to source the studies researchers and developers need. Led by CEO Martin Willemink, the company intends to use the Series A proceeds to further expand its medical imaging solutions for AI development and real-world evidence. Financially, Segmed raised $10.4M in a Series A and previously received financing from Flashpoint Growth Debt Fund in 2023. The company is headquartered in Palo Alto, California. Segmed offers a cloud-based real-world imaging platform, Segmed Insight, that enables medical researchers and AI developers to search, view studies and reports matching their criteria, and construct custom datasets. After placing an order users receive data in hand within days. The company has signed partnerships with healthcare systems, hospitals and imaging clinics across 1,000 locations on five continents. Led by CEO Martin Willemink, Segmed is based in Palo Alto, California. It raised $5.2M in a Seed+ round and has now raised more than $10M to date. The company intends to use the funds to accelerate growth, expand operations and broaden its business reach. Segmed is a secure, cloud-based platform that curates medical data by anonymizing, standardizing and labeling it to accelerate innovation in healthcare. Led by co-founder and CEO Cailin Hardell, the company partners with diverse healthcare providers around the world to source data. It standardizes and indexes medical data via a sequence of proprietary algorithms and enables customers to build customized datasets. Segmed positions itself as a shop for rapid, low-cost data aggregation and standardization for medical AI development. The company maintains strict HIPAA compliance and only uses and shares data that is fully anonymized. Financially, Segmed closed a $2M seed funding round in March 2020 to support its platform.

Led · Series A · Jul 2024

RetiSpec develops AI solutions applied to non-invasive retinal images to identify neurodegenerative disease markers and provide real-time results at the point of care. Its first clinically validated AI is intended to predict amyloid burden to aid evaluation for Alzheimer’s disease. RetiSpec’s solutions are currently available for Research Use Only. The company aims to enable widespread early and accurate detection of neurodegenerative disease through a routine eye exam. Leadership is headed by co-founder and CEO Eliav Shaked. The company is based in Toronto, Canada and has raised $17M USD to date.

Participated · Series C · Mar 2024

Flosonics Medical is a Canadian medical device company (founded 2015, Sudbury, Ontario) that develops FloPatch, a wireless wearable Doppler ultrasound designed to deliver rapid, repeatable hemodynamic assessments at the bedside. FloPatch aims to help clinicians assess fluid responsiveness and streamline critical decisions in sepsis and other acute-care settings, reducing fluid-related complications and improving patient outcomes. The company positions the device as a faster, more accessible alternative to traditional Doppler ultrasound machines in emergency and intensive care environments. Flosonics says the funding will accelerate market adoption and enable broader hospital deployment across North America and beyond. The announcement highlights the company’s focus on non-invasive, data-driven solutions and ongoing clinical research to support its technology. Financially, Flosonics secured venture debt to support scaling operations and commercialization efforts. Flosonics Medical develops FloPatch, a first-in-class wearable Doppler ultrasound designed for hemodynamic assessments. The device is intended to improve management of critically ill patients and support monitoring both inside and outside the hospital. The company emphasizes continued evidence generation to validate clinical use. Flosonics plans to expand indications for use and accelerate commercial growth and market adoption. The firm is a Canadian medical device company based in Sudbury, Ontario, founded in 2015. Recent financing will be used to support innovation, expansion, and broader deployment of its wearable AI-assisted sensor technology. Flosonics Medical is a venture-backed medical device company developing the FloPatch, a low-cost, wearable Doppler ultrasound sensor that adheres to a patient’s neck and sends hands-free blood flow data wirelessly via low-energy Bluetooth. The company says FloPatch enables on-demand, non-invasive Doppler measurement of blood flow to support management of critically ill patients across emergency, OR, ward, and ICU settings. Its first product, the FloPatch FP 120, has received regulatory clearances from the FDA and Health Canada. Founded in 2015 and headquartered in Sudbury, Ontario, Flosonics employs over 20 people focused on R&D. Financing proceeds will be used for a commercial launch in North America and for new product development as the technology transitions to clinical use.

Led · Seed · Mar 2022

Curv Health offers a full‑stack digital clinic platform that connects members from employers and insurance carriers to independent providers (physiotherapists, psychotherapists, counselors, dietitians, certified diabetes educators) via a suite of digital tools and a dedicated health concierge. Its remote monitoring suite includes computer vision, surveys, photo submissions, and integrations with Apple Health Kit sleep and heart‑rate data to support at‑home treatments. Curv reports its remote monitoring drives over 50% patient compliance to at‑home treatments (about 2x the industry norm), and the platform pays providers nearly 2x higher percentage per session than traditional clinics. The company emphasizes automation and new care pathways to reduce resource needs, lower costs, and improve long‑term health outcomes across physical, nutritional, and mental health. The recent CAD$5.1M seed financing will fund continued product development and hiring as part of an aggressive growth strategy. Curv is expanding partnerships with large insurance carriers, group benefits brokers, and employers and plans to launch into key U.S. markets in 2022. Curv Health's platform extracts physical health and performance metrics and biomechanical features from two-dimensional mobile video using computer vision and machine learning. The tool is targeted at athletes, coaches, trainers and health professionals to help diagnose and predict movement pathologies and inform preventative and rehabilitative care. The company plans to expand its SaaS offering directly to health and educational institutions across North America. Curv was founded in 2017 and had been bootstrapped through licensing its technology via API prior to this raise. The company has signed a deal with ASICS (also an investor) and has reported early revenue and partnerships, with past reports noting engagements with NBA teams and more than 500 universities and colleges. Curv is an alumnus of Next AI and ASICS Tenkan Ten, has opened an office in Halifax, and won the NFL’s "1st & Future" competition.